Sponsors
The bill clarifies and strengthens federal control over mifepristone—providing clearer regulatory standards and legal remedies while reinstating an older REMS—but does so at the cost of reduced access for many patients, greater liability and operational burdens for providers and carriers, and less regulatory flexibility for the FDA.
Clinicians, pharmacies, and patients who receive medication abortion will operate under a single, reinstated June 2011 REMS standard, clarifying permitted distribution pathways (including pharmacy dispensing and mail-order as allowed by that REMS) and potentially improving short-term access.
Clinicians, pharmacies, and health systems will face less regulatory uncertainty because the bill fixes the REMS standard, making enforcement and compliance expectations clearer.
Pregnant people and prescribing providers will have clearer statutory language that 'covered medication' refers to mifepristone, reducing ambiguity about which drug the Act protects and thereby lowering litigation risk over that identification.
Women and patients who rely on medication abortion or mailed medications will face reduced access to mifepristone nationwide and will be unable to receive imported doses, disrupting care and narrowing treatment options.
Telehealth providers, pharmacies, and logistics/carrier firms will face increased liability risk from expanded civil exposure, which could raise service costs, prompt insurers to change coverage, or reduce availability of tele-prescribing and pharmacy dispensing.
Patients and public-health outcomes could be harmed because reinstating and locking in the June 2011 REMS prevents the FDA from updating safety controls based on new evidence, limiting regulatory flexibility.
Based on analysis of 5 sections of legislative text.
Introduced May 6, 2025 by Joshua David Hawley · Last progress May 6, 2025
Requires the Department of Health and Human Services to restore and lock in the June 2011 FDA safety-restrictions (REMS) for the drug mifepristone within 90 days and forbids any different REMS going forward. Establishes a federal civil cause of action allowing people harmed by use of mifepristone to sue telehealth providers, pharmacies, importers, or others who knowingly handled the drug, and amends the Food, Drug, and Cosmetic Act to ban importation or mailing of mifepristone into the United States (no exceptions stated in the provided text). The civil remedy becomes effective 90 days after enactment; the bill sets a 90-day deadline for the REMS action and does not specify an effective date for the import ban in the provided text.